Dataset Information


Selective modulation of the androgen receptor AF2 domain rescues degeneration in spinal bulbar muscular atrophy.

ABSTRACT: Spinal bulbar muscular atrophy (SBMA) is a motor neuron disease caused by toxic gain of function of the androgen receptor (AR). Previously, we found that co-regulator binding through the activation function-2 (AF2) domain of AR is essential for pathogenesis, suggesting that AF2 may be a potential drug target for selective modulation of toxic AR activity. We screened previously identified AF2 modulators for their ability to rescue toxicity in a Drosophila model of SBMA. We identified two compounds, tolfenamic acid (TA) and 1-[2-(4-methylphenoxy)ethyl]-2-[(2-phenoxyethyl)sulfanyl]-1H-benzimidazole (MEPB), as top candidates for rescuing lethality, locomotor function and neuromuscular junction defects in SBMA flies. Pharmacokinetic analyses in mice revealed a more favorable bioavailability and tissue retention of MEPB compared with TA in muscle, brain and spinal cord. In a preclinical trial in a new mouse model of SBMA, MEPB treatment yielded a dose-dependent rescue from loss of body weight, rotarod activity and grip strength. In addition, MEPB ameliorated neuronal loss, neurogenic atrophy and testicular atrophy, validating AF2 modulation as a potent androgen-sparing strategy for SBMA therapy.


PROVIDER: S-EPMC5975249 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC4096235 | BioStudies
2009-01-01 | S-EPMC4209964 | BioStudies
2007-01-01 | S-EPMC4075031 | BioStudies
2014-01-01 | S-EPMC4356525 | BioStudies
2009-01-01 | S-EPMC2656163 | BioStudies
1000-01-01 | S-EPMC3030474 | BioStudies
2015-01-01 | S-EPMC4577982 | BioStudies
2009-01-01 | S-EPMC2735765 | BioStudies
1000-01-01 | S-EPMC5259768 | BioStudies
2014-01-01 | S-EPMC4180729 | BioStudies